Suppliers / Hubei Enoray Biopharmaceutical

Hubei Enoray Biopharmaceutical

China Updated 9 July 2026

Hubei Enoray Biopharmaceutical is an API manufacturer based in China. It holds 3 active US drug master files across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 13 March 2025 as NAI.

3
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 13 March 2025 NAI US FDA
  • 27 July 2017 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3010165284

What they file, and where

Molecule Regulators Docs
Heparin Sodium US FDA 2
Enoxaparin US FDA 1

Also appears on these molecule pages

Heparin API

Filings and GMP by regulator

Regulator Filings GMP certificates
INVIMA (CO) 1 None
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Hubei Enoray Biopharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 13 March 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates